The 2026 Healthtech Messaging Index
Imvaria
imvaria.com·scored September 1, 2026
15/38
Weak
The signal is faint. Most of this page is about Imvaria, not the buyer, and AI has little it can repeat. There's a lot of room to move.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for AI-powered medical diagnostic software for interstitial lung disease and pulmonary fibrosis, it named:
Buyer we put in the prompt: Pulmonologist or interventional radiologist at a US hospital or health system evaluating AI diagnostic tools for interstitial lung disease. Both the buyer and the category were inferred from Imvaria’s homepage alone. The model had no web access.
Imvaria was not on the list.
A buyer who asked AI this question got 8 names and moved on. Imvaria never came up.
We asked AI who it recommends for "Pulmonologist or interventional radiologist at a US hospital or health system evaluating AI diagnostic tools for interstitial lung disease" looking for "AI-powered medical diagnostic software for interstitial lung disease and pulmonary fibrosis". It named Imbio, VIDA Diagnostics, Tempus AI, Optellum, Veracyte. You did not appear. AI can't recommend what it can't clearly understand.
Overall assessment
IMVARIA's biggest strength is its demonstrated, hard-to-replicate authority: FDA De Novo authorization, Breakthrough Device Designation, AMA CPT code adoption, Mayo Clinic collaboration, and Google/Stanford founders are all concrete and distinctive. The biggest gap is that the homepage is entirely a press release archive with zero conversion architecture ... no hero, no buyer-facing narrative, no CTA, and no promised land for the clinician ... meaning a visiting pulmonologist has no guided path and no reason to act.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
01The 7-Second Test
“The scraped homepage content is entirely press releases ... no hero section, tagline, or above-the-fold narrative visible.”
A stranger landing on this page sees a press release wall, not a clear who/what/why statement answerable in 7 seconds.
All 19 signals, scored 0 to 2.
Total 15/38
Narrative Clarity
8 signals
- 0
01The 7-Second Testweakest
“The scraped homepage content is entirely press releases ... no hero section, tagline, or above-the-fold narrative visible.”
A stranger landing on this page sees a press release wall, not a clear who/what/why statement answerable in 7 seconds.
- 0
02Rebellion / Movement
“No named enemy, status quo critique, or industry pattern the company is pushing against anywhere in the content.”
The page celebrates milestones and describes products; it never names what broken system or incumbent approach IMVARIA is rebelling against.
- 1
03Owned Language & Category
“'Digital Biomarker Lab' and 'software-as-medical-device (SaMD) company pioneering AI-driven digital biomarker solutions'”
The term 'digital biomarker' is used consistently and product names Fibresolve and ScreenDx are coined, but the broader category frame is not owned or defined in a way AI would quote as IMVARIA's invention.
- 1
04ICP Clarity
“'thousands of pulmonologists who treat patients with lung disease'”
Pulmonologists are implied as the buyer but role, institution size, and buying context are never made explicit in a scannable way.
- 1
05Problem Leadership
“'nearly two-and-a-half-year delay in the diagnosis from the initial manifestation of symptoms'”
The problem (diagnostic delay in lung fibrosis) is mentioned, but it's buried inside a press release body, not leading the page as a buyer-centric problem statement.
- 1
06Solution Clarity
“'AI to guide safe, non-invasive diagnosis of lung fibrosis' and 'automatically assessing for interstitial lung findings compatible with interstitial lung disease'”
A persistent reader can piece together what Fibresolve and ScreenDx do, but there is no single hero sentence that cleanly explains the full offering in one pass.
- 1
07Cost of Inaction
“'severe lung impairment and even death can happen within one to two years from the onset of lung fibrosis'”
The cost of inaction for patients is mentioned, but the cost of inaction for the clinician buyer (missed diagnoses, liability, reimbursement gaps) is never named.
- 0
08Promised Land
“No 'after state' or promised land described for the clinician buyer ... no vision of transformed workflows, outcomes, or practice described.”
The page never paints a concrete picture of what a pulmonologist's practice looks like after adopting Fibresolve or ScreenDx.
Trust Signal
4 signals
- 1
09Proof & Evidence
“'over 125,000 deaths have occurred due lung cancer' and 'save thousands of dollars per person for each test'”
Epidemiological statistics and a vague cost-savings claim are present, but there are no before/after clinical performance numbers (sensitivity, specificity, accuracy deltas) for IMVARIA's own tools.
- 1
10Social Proof
“'Joshua Mooney, MD, MS, Clinical Assistant Professor, Medicine ... Pulmonary, Allergy & Critical Care at Stanford Medicine'”
One named clinician quote exists and Mayo Clinic is named as a collaborator, but there are no customer logos, video testimonials, or named health system case studies showing adoption at scale.
- 2
11Authority & Credibility
“'Founded in 2019 by physician-engineers from Google and Stanford University' and 'first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes by the American Medical Association'”
FDA De Novo authorization, Breakthrough Device Designation, AMA CPT codes, Mayo Clinic collaboration, and Google/Stanford founder credentials are all concrete, demonstrated authority signals.
- 0
12Alternatives Acknowledged
“No mention of competing diagnostic approaches, surgical biopsy as a named alternative, or 'do nothing' framing from the buyer's perspective.”
The page never honestly addresses what clinicians are doing instead of IMVARIA's tools or why those alternatives fall short.
AI Signal
6 signals
- 0
13Customer Focus
“Every section opens with 'IMVARIA announces,' 'IMVARIA receives,' 'IMVARIA enters' ... the company is the protagonist throughout.”
The page is entirely company-centric milestone broadcasting; the clinician buyer's transformation or journey is never centered.
- 1
14AI-Parmesan Index
“'leveraging AI, machine learning and deep-learning models' and 'AI-trained algorithm to provide non-invasive adjunct information'”
AI claims are frequent but the mechanism (what the CT ML classifier actually measures, how the algorithm was trained, performance stats) is described in vague terms rather than specific, citable mechanics.
- 1
15LLM Quotability
“'first FDA authorization of a diagnostic tool of any type in lung fibrosis, and the first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes by the American Medical Association'”
This sentence is quotable and distinctive, but it is buried in a press release rather than being surfaced as a clean, standalone declarative statement an LLM could cite in a recommendation.
- 2
16Copyright Freshness
“'Berkeley, Calif. ... May 18, 2025' and 'Berkeley, Calif. ... January 13, 2025'”
Press releases are dated through May 2025, providing strong recency signals that AI engines can weight positively.
- 2
17Entity Distinctiveness
“'first ever FDA-authorized AI adjunctive diagnostic service of any type in lung fibrosis' and 'first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes'”
The FDA De Novo authorization, named products Fibresolve and ScreenDx, Mayo Clinic partnership, and physician-engineer founders create a combination no competitor can replicate verbatim.
- 0
18AI Recommendation Check
“AI's picks: Imbio, VIDA Diagnostics, Tempus AI, Optellum, Veracyte, Intelerad. You were not named.”
We asked AI who it recommends for "Pulmonologist or interventional radiologist at a US hospital or health system evaluating AI diagnostic tools for interstitial lung disease" looking for "AI-powered medical diagnostic software for interstitial lung disease and pulmonary fibrosis". It named Imbio, VIDA Diagnostics, Tempus AI, Optellum, Veracyte. You did not appear. AI can't recommend what it can't clearly understand.
Conversion Signal
1 signal
- 0
19Path & CTA Clarity
“No CTA buttons, no numbered process steps, no 'request a demo' or 'contact us' path visible anywhere in the scraped content.”
The entire page is press releases with no conversion architecture ... no primary CTA, no soft secondary, and no process path for a clinician buyer to take action.
Your move
Think Imvaria’s score is wrong? Good. Let’s look at it together.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Imvaria the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.